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Many neurodegenerative diseases are characterized
by the presence of intracellular protein aggregates,
resulting in alterations in autophagy. However, the
consequences of impaired autophagy for neuronal
function remain poorly understood. In this study,
we used cell culture and mouse models of huntingtin
protein aggregation as well as post-mortem material
from patients with Huntington’s disease to demon-
strate that Argonaute-2 (AGO2) accumulates in the
presence of neuronal protein aggregates and that
this is due to impaired autophagy. Accumulation of
AGO2, a key factor of the RNA-induced silencing
complex that executes microRNA functions, results
in global alterations of microRNA levels and activity.
Together, these results demonstrate that impaired
autophagy found in neurodegenerative diseases
not only influences protein aggregation but also
directly contributes to global alterations of intracel-
lular post-transcriptional networks.INTRODUCTION
MicroRNAs (miRNAs) are small non-coding RNAs that provide
post-transcriptional control of gene expression. miRNAs play
an important role in the brain, where hundreds of different
miRNAs are expressed and thought to regulate thousands of
transcripts (Petri et al., 2014). Several lines of evidence indicate
that miRNAs are likely to play an important role in neurodegener-
ative diseases (NDDs) (Maciotta et al., 2013). For example, con-Cell R
This is an open access article under the CC BY-Nditional deletion of Dicer, a key enzyme in the miRNA biogenesis
pathway, results in neuronal cell death (Pang et al., 2014). In
addition, there are numerous reports describing changes in
miRNA expression levels in NDDs such as Alzheimer’s disease
(AD), Parkinson’s disease (PD), Huntington’s disease (HD), and
amyotrophic lateral sclerosis (ALS) (Maciotta et al., 2013). It is
therefore likely that alterations in miRNA levels participate in
the pathophysiological events underlying cell dysfunction and
loss in these diseases.
AD, PD, HD, ALS, and other diseases form a large class of
NDDs known as proteinopathies, characterized by the formation
of specific protein aggregates in the brain. Neurons appear to be
particularly sensitive to aggregation-prone proteins, indicating
that neuronal survival is highly dependent on maintaining effi-
cient protein quality control with rapid removal of toxic and
aggregated proteins (Cortes and La Spada, 2014). However, it
remains unclear how protein aggregation influences intracellular
functions and why specific neuronal subtypes ultimately are lost
in these different disorders. For example, it is well established
that neuronal gene expression programs are severely altered
in these disorders, but mechanistic insight into how neuronal
protein aggregation results in selective disturbances in transcrip-
tional networks is currently lacking.
Macroautophagy (hereafter referred to as autophagy) is an
evolutionary conserved lysosomal degradation pathway char-
acterized by the formation of an autophagosome, a double-
membraned vesicle that isolates the cytoplasmic cargo for
destruction (Martin et al., 2015). The autophagosome ulti-
mately fuses with a lysosome, forming the autolysosome
where the cargo is degraded. Several studies have docu-
mented altered autophagy in NDDs, and boosting autophagy
has been proposed as a novel therapeutic strategy (Martin
et al., 2015). In addition to clearing toxic and misfoldedeports 24, 1397–1406, August 7, 2018 ª 2018 The Author(s). 1397
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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proteins, we and others have recently found that autophagy
also plays a critical role in maintaining brain homeostasis
through selective protein degradation (Petri et al., 2017; Yama-
moto and Yue, 2014). One possibility is therefore that alter-
ations of autophagy in NDDs also directly influence other intra-
cellular neuronal functions.
One protein that is of interest in this regard is Argonaute-2
(AGO2), which is degraded by selective autophagy under basal
conditions (Gibbings et al., 2012). AGO2 is a core component
of the RNA-induced silencing complex (RISC), which executes
miRNA functions. In the RISC, AGO2 hasmultiple roles, including
biogenesis and maturation of miRNAs, as well as direct binding
of mature miRNAs (Petri et al., 2014). AGO2 also provides endor-
ibonuclease activity that enables direct degradation of miRNA
target transcripts, as well as recruitment of other downstream
factors that mediate transcriptional repression or decay (Bosse´
and Simard, 2010). Several studies have shown that intracellular
AGO2 protein is carefully titrated at a post-transcriptional level
and that miRNA-free AGO2 is degraded through a specific
mechanism (F€ullgrabe et al., 2014). Removal of mature miRNAs
by deleting the miRNA biogenesis factors Dgcr8 or Dicer results
in a parallel reduction of AGO2 protein levels (Gibbings et al.,
2012; Savas et al., 2008). Furthermore, overexpression of
AGO2 is very difficult to achieve, further suggesting a feedback
regulation of AGO2 protein levels (F€ullgrabe et al., 2014; He
et al., 2012). Together, these observations indicate that the regu-
lation of intracellular AGO2 protein levels is critical in maintaining
appropriate miRNA activity.
In this study, we used both cell culture and mouse models as
well as post-mortem material from patients with HD to demon-
strate that AGO2 accumulates as a result of impaired autophagy
in neurons expressing aggregating mutant Huntingtin (mHTT).
This AGO2 accumulation results in a global alteration of miRNA
activity. Our results provide mechanistic insights into how
impairment in autophagy in NDDs contributes to dysregulation
of miRNA networks.Figure 1. mHTT Expression Alters Autophagy and Results in Accumul
(A) Diagrams of the lentivrus (LV)-mHTT and LV-wtHTT vectors and the experime
(B) There was an elevated expression of AGO2 protein in mHTT-expressing cell
or W in LV-wtHTT-overexpressing cells. AGO2 protein is marked with an asteris
(C) There was no change in the mRNA level of the AGO2 protein in LV-mHTT- or
(D) Diagrams of the AAV-mHTT and AAV-wtHTT vectors and the experimental w
(E–H) Time-dependent accumulation of HTT was present in AAV-mHTT injected a
(H) Number of HTT aggregates/ mm2. n = 45 (3 animals/ group).
(I) AGO2 protein accumulates after 3 weeks in AAV-mHTT-injected animals. AGO
(J) AGO2 mRNA levels were not changed 3 weeks after mHTT overexpression. n
(K) Relative AGO2 mRNA levels were not changed 3 weeks after mHTT overexp
(L–N) AGO2 protein accumulates in AAV-mHTT (M), but not in AAV-wtHTT (L)-injec
bigger puncta in the AAV-mHTT-injected mice than in those injected with AAV-w
(O–R)WB autophagic protein expression levels in AAV-mHTT andwtHTT-injected
LC3-II (Q) and LC3-II/LC3-I ratio (R) are detected 3 weeks after AAV-mHTT injec
(S) Accumulation of LAMP1 was seen after 3 weeks in AAV-mHTT-injected but no
for wtHTT and mHTT, respectively (4 animals/ group).
(T–V) IHC demonstrate p62 accumulation in the AAV-mHTT (U) compared to A
significantly increased in mHTT-overexpressing animals compared to wtHTT 8 w
animals, respectively (3 animals/ group).
WB values were normalized to LV-wtHTT non-treated (B) or AAV-wtHTT (I and O–
0.05; nonparametric Kruskal-Wallis test was used for (B); two-tailed two-sample
mean ± SEM. Scale bars represent 50 mm (E–G), 10 mm (L and M), and 10 mm (TRESULTS
mHTT-Mediated Impairment of Autophagy Correlates
with Accumulation of AGO2
To investigate a potential link between alterations in autophagy
in NDDs and AGO2 expression levels, we transduced 293T cells
with lentiviral vectors expressing exon 1 of wild-type HTT
(wtHTT, 18 polyQ repeats) or mutant HTT (mHTT 66Q, 66 polyQ
repeats) (Figure 1A). HTT is mutated in HD, where a polyglut-
amine expansion in the first exon ultimately leads to a toxic
gain of function for mHTT and protein aggregation (DiFiglia
et al., 1997). Vector transduction was also combined with
chloroquine (CQ) treatment, which prevents both the fusion of
the autophagosome with the lysosome and lysosomal protein
degradation, or with wortmannin (W) treatment, a phosphatidyli-
nositol 3-kinase (PI3K) inhibitor that provides an early block of
autophagy and inhibits microtubule-associated protein 1A/1B-
light chain 3 (LC3) lipidation. Using this system, we monitored
autophagic activity by assessing the levels of LC3II, LC3-II/ I
ratio, p62, and LAMP1 using western blot (WB) and immunocy-
tochemistry (ICC) and found, in line with other studies (Martin
et al., 2015), that expression of mHTTmediates a late-step block
of autophagy characterized by failure of fusion of the autophago-
some and the lysosome (Figures S1A–S1R).
We next investigated AGO2 expression levels using WB in
293T cells transduced with mHTT. We found a significant in-
crease in the AGO2 protein level compared to wtHTT-expressing
cells, whereas there was no difference in the AGO2 mRNA level
(Figures 1B, 1C, and S1S). A similar increase in AGO2 protein
was also seen inwtHTT-transduced cells whenwe inhibited auto-
phagy using CQ or W (Figures 1B, 1C, and S1S), whereas we
found no additive effect of mHTT expression after CQ or W treat-
ment. Together, these data demonstrate that mHTT-mediated
autophagy impairment results in accumulation of AGO2 at a
post-transcriptional stage in mHTT-expressing cells in a manner
similar to that seen following chemical autophagy inhibition.ation of AGO2 In Vitro and In Vivo
ntal workflow, showing transduction of 239T cells before assays.
s. AGO2 protein levels increased after autophagic impairment induced by CQ
k. n = 5.
LV-wtHTT-expressing 293T cells. n = 3.
orkflow.
nimals after 3 (F) and 8 (G) weeks, but not in AAV-wtHTT (E)-injected animals.
2 protein is marked with an asterisk. n = 8 (4 animals/ group).
= 3.
ression. n = 5.
ted animals 8weeks after injection. (N) There were significantly more, as well as
tHTT. n = 27 (3 animals/ group).
animals (O). Increased expression levels of the autophagic markers p62 (P) and
tions. n = 8 (4 animals/ group).
t in AAV-wtHTT-injected mice. LAMP1 is marked with an asterisk. n = 10 and 20
AV-wtHTT (T)-injected animals. (V) Relative p62 dot number and size were
eeks after injection. n = 19 and 24 for AAV-wtHTT- and AAV-mHTT-injected
S) expression levels and corrected to actin values. ***p < 0.001, **p < 0.01, *p <
unequal variance t tests were used for all other cases. All data are shown as
and U). See also Figures S1–S3 and S6 and Tables S1 and S3.
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AGO2 Accumulates in Striatal Neurons Expressing
mHTT
The most affected neuronal cell type in HD is medium spiny neu-
rons in the striatum. To study the role of mHTT in modulating
autophagy and AGO2 levels in striatal neurons in vivo, we gener-
ated adeno-associated viral (AAV) vectors expressing either
exon 1 wtHTT or mHTT under the control of the neuron-specific
synapsin promoter that were subsequently injected into the
striatum of the mouse brain (Figure 1D). Mice injected with
AAV-mHTT showed a progressive increase in intracellular
mHTT inclusions, whereas AAV-wtHTT did not develop such in-
clusions (Figures 1E–1H). We also found progressive loss of
DARPP-32 levels in AAV-mHTT-injected mice in the absence
of neuronal cell loss, indicating progressive dysfunction of stria-
tal medium spiny neurons (Figures S2A–S2E).
We next investigated AGO2 levels after AAV-mHTT injections
using WB and found an almost 3-fold increase 3 weeks post-in-
jection (Figure 1I). We did not observe any changes in AGO2
mRNA levels, as monitored by RNA sequencing (RNA-seq) or
by qRT-PCR (Figures 1J and 1K). When we investigated AGO2
expression in the striatum using immunohistochemistry (IHC)
with two different antibodies, we found cytoplasmic AGO2 pro-
tein accumulation in the animals injected with AAV-mHTT but
not in animals injected with AAV-wtHTT (Figures 1L–1N and
S3A–S3D). We did not see any colocalization between AGO2
and mHTT aggregates in animals injected with AAV-mHTT, sug-
gesting that AGO2 accumulation is not a result of direct binding
to HTT aggregates (Figures 1L–1N). We also investigated the
level of other AGO proteins in the presence of mHTT but did
not find any changes in the protein or mRNA level for AGO1
and AGO4 (Figures S3E–S3G). Together, these data show that
expression of mHTT in striatal neurons results in protein aggre-
gation that is associated with formation and accumulation of
AGO2 protein puncta.
Activation of Autophagy Reverses AGO2 Accumulation
in Striatal Neurons Expressing mHTT
We next investigated alterations in autophagy following AAV-
mHTT injections in the mouse brain. Using WB and IHC analysis
of dissected striatal tissue from mice injected with AAV-mHTT
and AAV-wtHTT, we found increased levels of p62 and LC3-II
as well as an increased LC3-II/I ratio, suggesting impaired auto-
phagosome-lysosome fusion or inhibition of lysosome-mediated
proteolysis (Figures 1O–1R, S3H, and S3I). We also found an in-
crease in the lysosomal marker LAMP1 (Figures 1S, S3J, and
S3K). We found no changes in the mRNA levels of any of these
markers, asmonitored by RNA-seq (Figures S3L–S3N). Confocal
analysis of HTT/p62 co-staining revealed numerous p62-positive
mHTT aggregates in AAV-mHTT animals (Figures 1T–1V). p62-
positive clusters were found to accumulate adjacent to the
protein aggregates, with significant p62 sequestration within ag-
gregates (Figure S3O). Although accumulated p62 and AGO2
puncta were often found in the same cells, we never saw coloc-
alization of these two proteins, which is in line with previous data
showing that AGO2 is degraded by autophagy in a p62-indepen-
dent manner (Figures S3P–S3S; Table S1; Gibbings et al., 2012;
Savas et al., 2008). In addition, AGO2 puncta never colocalized
with the autophagosomal marker LC3 in mHTT-expressing cells,1400 Cell Reports 24, 1397–1406, August 7, 2018whereas we found several examples of colocalization between
AGO2 and LC3 in wtHTT-expressing neurons, indicating that
AGO2 is selectively degraded by autophagy in neurons express-
ing the wt protein but not in neurons expressing the mutant pro-
tein (Figures S3T and S3U). Together, these results demonstrate
that expression of mHTT leads to a distinct impairment in auto-
phagy that correlates with the accumulation of AGO2.
To provide a mechanistic link between the decrease in auto-
phagy activity and AGO2 accumulation, we next overexpressed
Beclin-1 (BECN1), a positive regulator of autophagosome forma-
tion, together with mHTT in the mouse brain (Figures S4A and
S4B). Three weeks after co-delivery of AAV-mHTT and AAV-
BECN1, the number of p62 aggregates was dramatically lower
compared to animals injected with AAV-mHTT alone (Figures
2A–2C). We also measured the changes in the level of LC3
with WB and IHC to see whether there was increased autophagy
activity and found a significant increase in the level of LC3-II and
LC3-II/I ratio (Figure S4C). LC3-positive dots accumulated in
the co-injected animals around the mHTT aggregates (Figures
S4D and S4E). We did not detect any changes in the level of
LAMP1 using IHC or WB, indicating that BECN1 overexpression
did not affect the formation and amount of lysosomes or endo-
somes (Figures S4F–S4I). We also found that BECN1 accumu-
lated aroundmHTT inclusions, which is in linewith its association
with newly formed autophagosomes (Figures S4J–S4L).
Strikingly, AGO2 dot number and size were significantly
reduced in BECN1 co-expressing mice (Figures 2D–2F). Thus,
BECN1 co-overexpression decreased the number of p62 aggre-
gates and reduced AGO2 dot size and number, providing a
mechanistic link between autophagy and AGO2 accumulation.
It is worth noting that the number of HTT inclusionswas 3 times
less in co-injected mice than in animals injected with AAV-mHTT
only (Figures 2G–2I) and that the DARPP-32 levels in striatal pro-
jection neurons were significantly higher (Figure 2J), suggesting
that autophagy activation using AAV-BECN1 interferes with the
progression of the mHTT-associated disease phenotype.
AGO2 Accumulation in a HD Mouse Model and Post-
mortem HD Tissue
Although the AAV-mHTT model is a good tool to study protein
aggregation in neurons, it fails to recapitulate many of the fea-
tures of HD (e.g., pathology in non-neuronal cells). To investigate
a potential dysregulation of AGO2 in a more disease-relevant
model of HD, we used BACHD mice, which express full-length
mHTT with 97 glutamine repeats under the control of endoge-
nous HTT regulatory sequences (Gray et al., 2008). At 6 months
of age, which represents an early manifest stage, we found an
accumulation of p62 inclusions in striatal neurons of BACHD
mice that was not seen in striatal tissue from wt littermates
(Figures 3A–3D). We also detected AGO2 accumulation in stria-
tal tissue of BACHD mice but not in controls (Figures 3A–3C and
3E). These AGO2 puncta were primarily found in the cytoplasm
of cells with a neuronal morphology. As with the AAV-model,
we never saw colocalization of p62 and AGO2 protein, although
p62 aggregates and AGO2 puncta were often found in the same
cells (Figure 3F; Table S1).
We then performed IHC on post-mortem striatal material
from HD patients of different pathological grades and healthy
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(A–C) Co-injection of AAV-BECN1 and AAV-mHTT (B) reversed the aggregation of HTT and p62 compared to AAV-mHTT (A)-injected animals. (C) There was a
reduction in the number, but not in the size of p62 aggregates. n = 10 (3 animals/group).
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(G–I) IHC demonstrate decreased HTT aggregation in the co-injected animals (H) compared to the AAV-mHTT (G). (I) Overexpression of BECN1 greatly reduced
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variance t tests. All data are shown as mean ± SEM. Scale bars represent 37.5 mm (A, B, D, and E) and 50 mm (G and H). See also Figure S4.age-matched individuals (Table S2). We found AGO2 accumula-
tion in cells in striatal tissue of the HD patients but not in healthy
individuals (Figure 3G–3M). We also found accumulation of p62
adjacent to mHTT inclusions in the neurons that were not seen
in the striatal tissue of healthy individuals (Figures S5A and
S5B). Similarly, we did not see colocalization of p62 and AGO2
protein (Figure 3N; Table S1). These data demonstrate that
AGO2 accumulates in a HD mouse model as well as in HD
patients.
AGO2 Accumulation Results in a Global Increase in
miRNA Levels
AGO2 levels are directly related to the number of mature
miRNAs present within a cell (Diederichs and Haber, 2007).
This suggests that the increase in AGO2 levels that occursfollowing mHTT expression may result in an increased level of
mature miRNAs, which may be coupled to profound effects
on the activity of miRNAs. To investigate alterations in miRNA
levels, we performed small RNA-seq on striatal brain tissue
dissected 3 weeks after AAV-wtHTT and AAV-mHTT injections.
This time point was chosen because there were no major cell
death or phenotypic changes in the surrounding glia and only
minor electrophysiological alterations in striatal neurons, repre-
senting an early time point in the disease course (Figures S2F–
S2Q and S5C; Table S3). When investigating global miRNA
levels, we found a more than 50% global increase in mature
miRNA levels in AAV-mHTT-injected mice compared to AAV-
wtHTT-injected mice (Figures 4A and 4B). We found that
most individual miRNAs were overexpressed, including abun-
dant neuronal miRNAs such as miR-128, miR-9, and let-7Cell Reports 24, 1397–1406, August 7, 2018 1401
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Figure 3. p62 and AGO2 Accumulate in BACHD Mice and in Post-mortem Material from HD Patients
(A–E) p62 (D) and AGO2 (E) accumulate in the striatal tissue of BACHD mice (B and C) but not in wt animals (A). n = 18 (3 animals/ group).
(F) Li’s intensity correlation analysis shows that AGO2 and p62 have almost no colocalization, as indicated by the points mostly falling equally along the positive
and negative sides of the x axis. Ai: AGO2 intensity; Bi: p62 intensity.
(G–M) There was a clear accumulation of AGO2 (M) and p62 (L) in all of the HD post-mortem tissue (I–K) but not in the healthy control tissue (G and H). (L) For p62
statistical analysis, 542 and 1,658 DAPI+ cells were analyzed in 2 control and 3 HD patients, respectively. (M) For AGO2 statistical analysis, 772 and 2,032 DAPI+
cells were analyzed in 2 control and 3 HD patients, respectively.
(N) AGO2 and p62 puncta accumulated inside neurons and did not colocalize. Ai: AGO2 intensity; Bi: p62 intensity.
ND: non-detectable; ***p < 0.001; **p < 0.01; two-tailed two-sample unequal variance t tests. All data are shown as mean ± SEM. Scale bars represent 25 mm
(A and B), 5 mm (C), and 12.5 mm (G–K). See also Figure S5 and Tables S1 and S2.
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Figure 4. miRNAs and SGs Accumulate in Neurons Expressing Protein Aggregates
(A) Volcano plot summarizing the fold changes of all miRNAs after 3 weeks in AAV-mHTT-injected animals compared to AAV-wtHTT. n = 3 (8 animals/sample,
Wald chi-square test).
(B) Levels of mature miRNAs are increased in AAV-mHTT-injected animals compared to AAV-wtHTT-injected controls 3 weeks after injection. n = 3 (8 animals/
sample).
(C) Distribution of the most abundant miRNA families after 3 weeks of AAV-wtHTT-injected animals. n = 3 (8 animals/sample).
(D–F) TIA1 accumulated in AAV-mHTT (E)-injected animals compared to AAV-wtHTT (D). (F) Overexpression of mHTT significantly increased TIA1 size. n = 11 for
AAV-wtHTT and n = 9 for AAV-mHTT (3 animals/group).
(G) TIA1 protein level was significantly higher in AAV-mHTT-injected animals compared to AAV-wtHTT. n = 10 or 8 (5 animals in the AAV-wtHTT group and 4
animals in the AAV-mHTT-injected group).
(H) TIA1 showed increased colocalization with AGO2. n = 11 for AAV-wtHTT and n = 9 for AAV-mHTT (3 animals/group).
(legend continued on next page)
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(Figures 4C, S5D, and S5E). These data demonstrate that the
increase in AGO2 levels correlates with an increased level of
mature miRNAs.
AGO2 Puncta Localize to Stress Granules, Resulting in
Loss of miRNA Activity
The subcellular localization of AGO2 is known to be important for
the activity of miRNA-mediated gene silencing (Leung and
Sharp, 2013). This suggests that alterations of AGO2 levels as
well as accumulation of AGO2 in puncta in mHTT-expressing
neurons may affect the activity of miRNAs. AGO2 protein is nor-
mally diffusely distributed throughout the cytoplasm but has also
been found in processing bodies (P-bodies) and stress granules
(SGs) (Anderson and Kedersha, 2006; Leung and Sharp, 2013).
The shuffling of AGO2 through different cytoplasmic compart-
ments is directly related to the activity of miRNAs. For example,
AGO2 found in SGs contains miRNAs but does not participate in
gene silencing (Leung and Sharp, 2013).
In mice injected with AAV-mHTT, we found a 4-fold increase in
the size of SGs, as monitored with the cytotoxic granule-associ-
ated RNA binding protein TIA1 (Figures 4D–4F). We also found
an increase in total TIA1 levels, asmeasuredwithWB (Figure 4G).
Remarkably, we found a clear increase in the amount of AGO2
localizing to SGs in mHTT-expressing cells (Figures 4D, 4E,
and 4H; Table S1). On the contrary, we did not find a significant
increase in colocalization of AGO2 puncta to P-bodies (Figures
4I–4K; Table S1). We also found that overexpression of AAV-
BECN1, together with AAV-mHTT, significantly reduced TIA1
colocalization with AGO2 (Figures S5F–S5H; Table S1). These
data demonstrate that a substantial fraction of AGO2 re-local-
izes to SGs in mHTT-expressing neurons. Because AGO2-
miRNA complexes lose their silencing activity in SGs, this
indicates that an overall loss of miRNA activity should occur
following mHTT expression.
To test this hypothesis, we investigated neuronal miRNA
activity by performing RNA-seq on striatal tissue injected with
either AAV-mHTT or AAV-wtHTT and quantified the expression
of all detectable mRNAs. We then selected targets of three of
the most highly expressed neuronal miRNAs in the mouse
striatum, miR-128, let-7, and miR-9, based on computationally
predicted and evolutionary conserved miRNA target sites
(TargetScanMouse 7.1) (Figure 4L; Table S4; Agarwal et al.,
2015). We assessed the global fold change distribution of targets
in cumulative fraction graphs (y axis) and found that the expres-
sion levels of these miRNA targets, but not non-neuronal miRNA(I–K) Therewas no difference in the level of AGO2 co-staining with DCP1A between
not change DCP1A and AGO2 colocalization. n = 6 (3 animals/group).
(L) Venn diagram showing the number of unique and shared target genes of let-7, m
reads on average were included and used in the downstream miRNA target ana
(M) Cumulative fractions of log2(mHTT/wtHTT) fold changes of expressed genes (>
38 shared targets show a significant upregulation in AAV-mHTT compared to A
Wilcoxon rank-sum test with continuity correction was applied to target genes v
(N) The top 12 most enriched Panther gene ontologies among the set of significa
miR-128 target genes. Fold enrichment: observed number of genes/expected fro
p value, binomial distribution test. Numbers by bars indicate the number of obse
All fold changes are shown as log2(mHTT/wtHTT). WB values were normalized t
0.001; **p < 0.01; *p < 0.05; two-tailed two-sample unequal variance t tests. All da
(I and J). See also Figure S5 and Tables S1, S2, S4, S5, and S6.
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AAV-mHTT-injected animals, indicating a de-repression of tar-
gets of the most abundant neuronal miRNAs (Figures 4M and
S5I). Interestingly, genes targeted by all three miRNAs showed
an even stronger shift toward de-repression (Figure 4M).
Together, these results are in line with other studies where re-
localization of AGO2 to SGs is associated with a loss of miRNA
activity (Leung and Sharp, 2013; Qi et al., 2008; Wu et al., 2011).
To investigate the potential function of the de-repressed
miRNA targets, we performed gene ontology analysis on
the set of genes targeted by the three most abundant miRNAs
(let-7, miR-128, and miR-9) and found these to be highly en-
riched for terms such as neurological system processes, axon
guidance, and synaptic functions (Figures 4N and S5J). These
are all mechanisms that are disrupted in HD and other NDDs.
In an independent analysis, we also confirmed that experimen-
tally identified neuronal miR-128 targets were upregulated
upon mHTT expression (Figure S5K; Tan et al., 2013). It is worth
noting that the phenotype of miR-128 KO mice is characterized
by neuronal hyperactivity, a phenomenon that is also found in
models of HD, directly linking our analysis to HD-like phenotypes
(Tan et al., 2013).
DISCUSSION
Several hundred miRNAs are expressed in the brain and are
thought to regulate thousands of transcripts (Petri et al., 2014).
Therefore, any alteration in the miRNA network is likely to have a
significant effect on neuronal function. In line with this, there is
extensive literature documenting that conditional deletion ofDicer
or individual miRNAs such as miR-128 in postmitotic neurons
(including striatal neurons) results in phenotypes that are reminis-
cent of HD (Cheng et al., 2014; Schaefer et al., 2007; Tan et al.,
2013). Thus, an alteration in miRNA activity in HD and other
NDDs is likely to contribute to the early intracellular pathology,
including alterations in neuronal activity and synaptic plasticity.
The current work provides mechanistic insight into how protein
aggregation causes global alterations of miRNA level and activity
through a direct link between impaired autophagy and AGO2
accumulation because of mHTT expression. Our results are in
line with previous studies demonstrating that selective autophagy
is required to maintain appropriate AGO2 levels and that AGO2
levels need to be carefully regulated to sustain appropriate levels
of mature miRNAs (F€ullgrabe et al., 2014; Gibbings et al., 2012;
He et al., 2012; Savas et al., 2008). However, a previous studyAAV-wtHTT (I) andmHTT (J)-injected animals. (K) Overexpression ofmHTT did
iR-9, andmiR-128, as predicted by TargetScan. Only genes withmore than 16
lysis. n = 3 (1 animal/ RNA sample).
16 reads) and the predicted targets of let-7, miR-9, and miR-128 as well as the
AV-wtHTT-injected animals. n = 3 (1 animal/sample). *p < 0.05, ***p < 0.001;
ersus all genes).
ntly upregulated (log2 fold-change > 0.1; *p < 0.05, n = 183) let-7, miR-9, and
m background population of all expressed genes (>16 reads). Black triangles:
rved genes for the given term.
o AAV-wtHTT-injected expression levels and corrected to actin values. ***p <
ta are shown as mean ± SEM. Scale bars represent 5 mm (D and E) and 7.5 mm
performed in cancer cell lines found that AGO2 accumulation
because of impaired autophagy results in a loss of mature
miRNAs. In this study, the authors speculated that this phenome-
nonwasdue toan imbalance in thestoichiometryof theRISCcom-
plex components (Gibbings et al., 2012). When we analyzed 293T
cells expressing mHTT, we found similar results, including global
loss of mature miRNAs (Figures S5L and S5M). However, mature
neurons do not divide, and, thus, any impairments in autophagy
are likely to have different consequences than in dividing cells,
which can renew their cytoplasmic content upon cell division.
We found that accumulation of AGO2 in neurons expressing
mHTT is linked to accumulation of mature miRNAs. However,
mHTT expression also causes a shift in AGO2 localization to
SGs, resulting in global loss of miRNA activity despite the in-
crease in mature miRNAs. It thus appears that the consequence
of AGO2 accumulation is fundamentally different between neu-
rons and dividing cells, which could be due to the inability of neu-
rons to renew their protein composition during cell division or
through the appearance of SGs in mHTT-expressing neurons.
In this study, we used an AAV-based in vivomousemodel. This
model has several advantages for studying the transcriptional
response to mHTT because it allows for an appropriate control
(AAV-wtHTT) and results in neuron-specific expression of
mHTT, limiting the effect on surrounding glial cells that otherwise
may complicate the analysis. Compared to most transgenic
mouse models of NDDs, it also avoids potential developmental
or compensatory effects that might arise because of transgene
expression in the entire organism during brain development.
Our data show that alterations in AGO2 levels following mHTT
expressionoccur at an early timepoint during thedisease course.
AGO2 and mature miRNAs are already accumulating 3 weeks
followingAAV-mHTT injection, a timepointwhenonlyminor alter-
ations in neuronal functions can be detected, as monitored by
DARPP-32 levels or electrophysiological recordings. This sug-
gests that loss ofmiRNAactivitymaybe an important component
of early disease phenotypes in HD. In this respect, our data are in
line with a previous study that found a global accumulation of
miRNAs at an early stage in a mouse model of HD, and there
are also data indicating that mHTT expression impairs miRNA
silencing in cell lines (Lee et al., 2011; Savas et al., 2008). In
contrast, our results are inconsistentwith several reports of either
selective up- or downregulation of individual miRNAs or reports
of a global loss of miRNAs in more severe HD mouse models or
when analyzing post-mortem tissue (Kocerha et al., 2014; Ma-
ciotta et al., 2013). This discrepancy may, to some extent, be ex-
plainedbydifferences inmethodology aswell as some limitations
when using various mouse models and post-mortem material.
Alternatively, it may also result from the fact that impairments of
the miRNA machinery change as the disease progresses. When
we analyzed striatal tissue 6 months after AAV-mHTT injection,
when there was clear evidence of striatal and ventricle volume
changes that was coupled with atrophy and gliosis, thus reflect-
ing a later-stage time point, we rather find a decrease in AGO2
protein level, asmeasured byWB, and only detected sparse neu-
rons displaying AGO2 accumulation (Figures S6A–S6Y). Similar,
we found lower AGO2 levels fromHD post-mortem striatal tissue
when analyzing global protein levels using WB (Figure S6Z).
These data raise the possibility that AGO2 accumulation accom-panied by a loss of miRNA activity is a specific feature of early-
stage impairment in neurons expressing protein aggregates
and impaired autophagy.
In summary, our results suggest that changes in miRNA levels
are an early feature of HD that lies downstream of alterations in
autophagy. Our data provide a mechanistic link between protein
aggregation and post-transcriptional gene regulation, two seem-
ingly unrelated phenomena. Our data also provide further support
for developing autophagy-activating therapeutic approaches for
HD and other NDDs because they suggest that activation of auto-
phagy will not only clear toxic protein aggregates but also directly
restore dysfunctional post-transcriptional gene regulation.
EXPERIMENTAL PROCEDURES
Detailed experimental procedures can be found in the Supplemental Experi-
mental Procedures.
Viral Vectors
To overexpress wtHTT and mHTT, we used previously described third-gener-
ation self-inactivating lentiviral vectors encoding the first 171 amino acids of
the human huntingtin gene with 18 or 66 CAG repeats under the control of a
mouse phosphoglycerate kinase 1 promoter (PGK) (de Almeida et al., 2002).
Animal Surgery
All animal-related procedures were approved and conducted in accordance
with the Committee for Use of Laboratory Animals at Lund University. All
mice were adult C57BL/6 females 9 to 10 weeks old at the time of surgery.
All stereotactic injections into the striatum were performed as described
before with minor changes (Petri et al., 2017). Injections were unilateral on
the right side of the brain with a total of 1 ml of injected virus. The injection co-
ordinates were as follows: anterior/posterior (AP): +0.9 mm; medial/lateral
(ML): +/1.8 mm; dorsal/ventral (DV) (from the dura): 2.7 mm.
Human Tissue
Post-mortem human brain tissue was obtained from the Cambridge Brain
Bank (Cambridge, UK) and used under local ethics approval (REC 01/177).
Small RNA-Seq
cDNA libraries of small RNA-seq samples were prepared using the New
England Biolabs Small RNA Library Prep Kit for small RNA-seq at the Clinical
Microarray Core (University of California, Los Angeles [UCLA], CA, USA).
Illumina high-throughput sequencing was applied to the samples (total number
of reads: in vivo, 228,894,902; in vitro, 71,800,132).
RNA-Seq
cDNA libraries of the in vitro mRNA samples were prepared using the KAPA
Stranded mRNA-Seq Kit from KAPAbiosystems at the Clinical Microarray
Core (UCLA, CA, USA). In vivo cDNA libraries were prepared using the Illumina
Strand-Specific TruSeq RNA Library Kit using poly(A) selection and sent for
sequencing to SciLifeLab. Illumina high-throughput sequencing was applied
to all the samples (total read number: in vitro, 180,491,336; in vivo, 356,983,073).
Statistical Analysis
Two-tailed, two-sample unequal variance t testswere used to analyzemeans in
most cases. One-way ANOVA or nonparametric Kruskal-Wallis test was used
in Figures 1B, S1B–S1D, S1M, and S1N with Figures S1Q and S1S depending
on normal distribution defined by D’Agostino-Pearson omnibus normality test.
The criterion for significance for all analyseswas p < 0.05. All data are shown as
mean ± SEM.
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